AstraZeneca
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
“We are pleased to see the sustained and meaningful survival benefit of Imfinzi for patients with small cell lung cancer after more than two years median follow up,” said Jose Baselga, Astra Zeneca’s executive vice president, Oncology R&D.
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
The primary endpoint was a statistically significant improvement in progression-free survival for the combination versus platinum-based chemotherapy.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
JOBS
IN THE PRESS